标题： The efficacy of myo-inositol supplementation to prevent gestational diabetes onset: a meta-analysis of randomized controlled trials.
作者： Xu, Jiang; Ye, Shandong
作者机构：[ Xu, Jiang; Xu J] a School of Medicine , Shandong University , Jinan , China., b Department of Endocrinology , Anhui Provincial Hospital , Hefei , Ch 更多
来源： The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
摘要： INTRODUCTION: The efficacy of myo-inositol supplementation to prevent gestational diabetes onset remains controversial. We conduct a systematic review and meta-analysis to explore the influence of myo-inositol supplementation on the incidence of gestational diabetes. METHODS: We search PubMed, Embase, Web of science, EBSCO, and Cochrane Library databases through November 2017 for randomized controlled trials (RCTs) assessing the effect of myo-inositol supplementation on gestational diabetes onset. This meta-analysis is performed using the random-effect model. RESULTS: Five randomized controlled trials (RCTs) are included in the meta-analysis. Compared with control group in pregnant women, myo-inositol supplementation is associated with significantly reduced incidence of gestational diabetes (risk ratio (RR) = 0.43; 95% CI = 0.21-0.89; p = 0.02), and preterm delivery (RR = 0.36; 95% CI = 0.17-0.73; p = 0.005), but has no substantial impact on 2-h glucose oral glucose tolerance test (OGTT) (mean difference (MD) = -6.90; 95% CI = -15.07-1.27; p = 0.10), gestational age at birth (MD = 0.74; 95% CI = -1.06-2.54; p = 0.42), birth weight (MD = -5.50; 95% CI = -116.99-105.99; p = 0.92), and macrosomia (RR = 0.65; 95% CI = 0.20-2.11; p = 0.47). CONCLUSIONS: Myo-inositol supplementation has some ability to reduce the incidence of gestational diabetes and preterm delivery in pregnant women.